Login to Your Account

GSK Paying $33M Up Front

Fragment-Based Platform Lands Another Early Stage Astex Deal

By Jennifer Boggs

Friday, November 13, 2009
Last year's crumbling markets might have forced Astex Therapeutics Ltd. to delay plans for an initial public offering, but the Cambridge, UK-based firm is hardly hurting for cash, thanks to fragment chemistry-based discovery deal with GlaxoSmithKline plc. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription